This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| enterovirus 71 | |
|---|---|
| Name | Enterovirus 71 |
| Virus group | IV (ssRNA(+)) |
| Family | Picornaviridae |
| Genus | Enterovirus |
enterovirus 71 is a small, non-enveloped, positive-sense single-stranded RNA virus in the family Picornaviridae and genus Enterovirus. It is a major cause of hand, foot, and mouth disease (HFMD) and can lead to severe neurological and cardiopulmonary complications. Outbreaks have prompted public health responses in countries including China, Taiwan, Malaysia, Singapore, and Japan.
Enterovirus 71 is a member of the Enterovirus genus within Picornaviridae and shares structural features with other picornaviruses such as Poliovirus and Coxsackievirus. The ~7.4 kb positive-sense RNA genome encodes a single polyprotein cleaved into structural proteins VP1–VP4 and nonstructural proteins 2A–3D, a layout comparable to Hepatitis A virus and Rhinovirus. Viral capsid proteins determine antigenic groups and receptor interactions; VP1 sequence variation defines genogroups (A, B, C, etc.) analogous to sequence-based typing used for Influenza A virus hemagglutinin subtypes. EV71 entry uses receptors such as scavenger receptor B2 and P-selectin glycoprotein ligand-1, mechanisms reminiscent of receptor usage studies for HIV-1 gp120 and Ebola virus glycoprotein. Viral replication occurs on rearranged intracellular membranes, a strategy studied across Dengue virus and West Nile virus research.
EV71 displays global circulation with marked regional outbreaks; major epidemics occurred in Malaysia (1997), Taiwan (1998), China (2008, 2010s), and Vietnam (2011). Transmission is fecal–oral and respiratory, paralleling patterns seen with Rotavirus and Influenza A virus in community spread. Age distribution skews to young children, similar to pediatric burden observed with Measles virus prior to widespread vaccination and Respiratory syncytial virus. Molecular surveillance employs genotyping like that used in Human papillomavirus and Norovirus monitoring to track emergence of new clades linked to increased virulence. International travel and urbanization factors associated with SARS-CoV-2 dissemination have also influenced EV71 spread.
Clinical presentation ranges from mild HFMD—maculopapular or vesicular lesions on hands, feet, and oral mucosa—to severe neurologic disease including aseptic meningitis, encephalitis, acute flaccid paralysis, and neurogenic pulmonary edema. Severe cases mirror complications historically seen with Poliovirus paralytic disease and neurologic sequelae described for Rabies virus and Japanese encephalitis virus. Fever, herpangina, and lethargy are common prodromal signs; rapid deterioration with autonomic dysregulation has been compared to crises in Diphtheria and fulminant forms of Influenza A (H5N1). Case-fatality ratios vary by outbreak and healthcare access, prompting comparisons with mortality patterns of Ebola virus and Hantavirus outbreaks in resource-limited settings.
EV71 pathogenesis involves primary replication in the oropharynx and gut with potential secondary invasion of the central nervous system via hematogenous spread or retrograde axonal transport, mechanisms that echo neuroinvasion models for Poliovirus, Herpes simplex virus, and West Nile virus. Host immune responses include innate sensing via pattern recognition receptors and adaptive neutralizing antibody responses largely directed at VP1, paralleling protective correlates established for Hepatitis A vaccine and Poliovirus vaccine. Immunopathology, including cytokine storm and autonomic dysfunction, has been implicated in severe cardiopulmonary collapse, with immunologic features resembling those noted in severe Influenza and SARS-CoV-2 infection. Cross-neutralization between genogroups is limited, informing vaccine design considerations akin to antigenic drift issues for Influenza vaccine.
Diagnosis relies on clinical recognition of HFMD and neurologic syndromes, supported by laboratory tests: viral culture in cell lines (e.g., RD cells), reverse transcription–polymerase chain reaction (RT-PCR) targeting VP1 or 5′-UTR, and serology measuring neutralizing antibodies. These methods parallel diagnostic pathways used for Poliovirus and West Nile virus infections. Molecular typing by sequencing of VP1 informs epidemiologic linkage as done in HIV-1 and Hepatitis C virus molecular epidemiology. Neuroimaging and cerebrospinal fluid analysis assist in assessing CNS involvement, comparably applied in Japanese encephalitis diagnostics.
Prevention emphasizes hygiene, surveillance, and vaccination. Licensed inactivated EV71 vaccines were developed and implemented in China following clinical trials comparable in rigor to those for Human papillomavirus vaccine and Rotavirus vaccine. Supportive care is the mainstay for most patients; severe cases require intensive care management, respiratory support, and autonomic stabilization similar to interventions used in fulminant Influenza and Dengue shock. Antiviral development has explored protease and polymerase inhibitors analogous to treatments targeting HIV-1 protease and Hepatitis C virus NS5B, but no broadly approved specific antivirals for EV71 are available universally.
First isolated in the 1960s, EV71 gained prominence after large outbreaks in the Asia–Pacific region during the late 20th and early 21st centuries, notably the 1997 Malaysia outbreak and the 1998 Taiwan epidemic. The virus has driven vaccination policy debates and surveillance strengthening similar to global responses to Poliomyelitis eradication efforts and outbreak control for SARS and Middle East respiratory syndrome coronavirus. Economic and healthcare burdens from EV71 outbreaks prompted inclusion in national vaccination programs and international collaboration in research, echoing public health initiatives for Measles elimination and Influenza pandemic preparedness. Ongoing monitoring by national public health agencies and collaboration among research institutions aims to mitigate future epidemics as for other vaccine-preventable infectious diseases.